Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Suzhou Haiyi Biomedical Technology Co., Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is handled by 1 distinct examiner and is located within 1 distinct art unit. The alignment of a single action with a single art unit suggests a focused examination path for the company's current intellectual property interests in the sector. This clarity in the prosecution path allows for a more predictable timeline for the applicant.
BABIC, CHRISTOPHER M is designated as the busiest examiner for this portfolio. This examiner is responsible for 1 busiest examiner pending action. Because the total number of pending office actions is 1, this individual manages the full extent of the company's current interactions with the patent office.
For practitioners, the concentration of 1 pending office action under 1 distinct examiner in the Biotechnology & Pharmaceuticals area allows for a specific response strategy. The data shows that the company's current legal focus is entirely contained within the workload of BABIC, CHRISTOPHER M, providing a clear point of contact for ongoing prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BABIC, CHRISTOPHER M | 1 | 60.6% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557993 | SUBSTANCE HAVING HIGH ACTIVITY AND HIGH SAFETY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN DRUG | BABIC, CHRISTOPHER M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557993 | SUBSTANCE HAVING HIGH ACTIVITY AND HIGH SAFETY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN DRUG | BABIC, CHRISTOPHER M | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557993 | SUBSTANCE HAVING HIGH ACTIVITY AND HIGH SAFETY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN DRUG | BABIC, CHRISTOPHER M | 1633 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Haiyi Biomedical Technology Co., Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christopher M Babic has the most, with 1 of Suzhou Haiyi Biomedical Technology Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
